Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series

Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series

Patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) following autologous stem cell transplant (ASCT) remain a management challenge with few reliably effective treatments. Lenalidomide, an immunomodulatory drug approved for patients with myelodysplastic syndrome with del(5q),...

Full description

Bibliographic Details
Main Authors: Helen Ma, Bin Cheng, Francesca Montanari, Jennifer K. Lue, Changchun Deng, Enrica Marchi, Owen A. O’ Connor, Ahmed Sawas
Format: Article
Language:English
Published: SAGE Publishing 2020-09-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/2040620720947340

Internet

https://doi.org/10.1177/2040620720947340

Similar Items